Compounds > n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
Page last updated: 2024-09-03

n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Cortex Cancer

n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea has been researched along with Adrenal Cortex Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chugh, R; Fassnacht, M; Habra, MA; Ijzerman, MM; Jafarinasabian, P; Kebebew, E; Kroiss, M; Lin, VH; Mohideen, P; Naing, A; Schneider, BJ; Smith, DC1

Trials

1 trial(s) available for n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Cortex Cancer

ArticleYear
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
    Investigational new drugs, 2020, Volume: 38, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Female; Humans; Male; Middle Aged; Sterol O-Acyltransferase; Tablets; Urea

2020